Trends in the incidence and survival of multiple myeloma in South East England 1985-2004

[1]  S. Schey.  Survival from multiple myeloma in England and Wales up to 2001 , 2008, British Journal of Cancer.

[2]  M. Coleman,et al.  Survival from multiple myeloma in England and Wales up to 2001 , 2008, British Journal of Cancer.

[3]  B. Wiedenmann,et al.  Inducible re-expression of p16 in an orthotopic mouse model of pancreatic cancer inhibits lymphangiogenesis and lymphatic metastasis , 2008, British Journal of Cancer.

[4]  B. Barlogie,et al.  Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. , 2009, Blood.

[5]  D. Dingli,et al.  Improved survival in multiple myeloma and the impact of novel therapies. , 2008, Blood.

[6]  H. Brenner,et al.  Recent major improvement in long-term survival of younger patients with multiple myeloma. , 2008, Blood.

[7]  J. Harousseau.  Induction therapy in multiple myeloma. , 2008, Hematology. American Society of Hematology. Education Program.

[8]  A. Cheng,et al.  Epidemiology of multiple myeloma in Taiwan , 2007, Cancer.

[9]  P. Dickman,et al.  Patterns of survival in multiple myeloma: a population-based study of patients diagnosed in Sweden from 1973 to 2003. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  B Møller,et al.  The future burden of cancer in England: incidence and numbers of new patients in 2020 , 2007, British Journal of Cancer.

[11]  H. Adami,et al.  Multiple myeloma: A review of the epidemiologic literature , 2007, International journal of cancer.

[12]  L. Bernstein,et al.  Risk patterns of multiple myeloma in Los Angeles County, 1972–1999 (United States) , 2006, Cancer Causes & Control.

[13]  D. Samson,et al.  Guidelines on the diagnosis and management of multiple myeloma 2005 , 2006, British journal of haematology.

[14]  D. Bevan,et al.  A population study to define the incidence and survival of multiple myeloma in a National Health Service Region in UK , 2004, British journal of haematology.

[15]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[16]  Leila Mohammadi,et al.  BMC Cancer , 2001 .

[17]  H O Dickinson,et al.  Cancer trends in England and Wales , 2000, BMJ : British Medical Journal.

[18]  R. Sadovsky,et al.  Multiple myeloma: recognition and management. , 1999, American family physician.

[19]  O. Gefeller,et al.  An alternative approach to monitoring cancer patient survival , 1996 .

[20]  A. Adelstein.  Studies on medical and population subjects. , 1976 .

[21]  A I Pick,et al.  THE TREATMENT OF MULTIPLE MYELOMA , 1948, Harefuah.